Trial Profile
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Poly ICLC; Rasdegafusp-alfa
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Jan 2023 Primary efficacy and safety endpoint measures amended.
- 20 Jul 2021 Status changed from active, no longer recruiting to completed.
- 30 Apr 2021 Planned End Date changed from 27 Mar 2022 to 20 Aug 2021.